title: Adverse effects of glucocorticoid therapy for inner ear disorders.
abstract: BACKGROUND
  Because of their anti-inflammatory effects and suppression of the immune system, glucocorticoids have been widely used in otolaryngologic disorders and perioperative conditions.
  
  
  OBJECTIVE
  The objective of the present study was to determine the incidence of adverse effects after the administration of glucocorticosteroids in patients affected by diverse inner ear disorders.
  
  
  METHODS
  One hundred and sixty-three patients affected by sudden sensorineural hearing loss, 39 with progressive sensorineural hearing loss and 16 with fluctuating sensorineural hearing loss were subjected to glucocorticosteroid therapy with 6-methylprednisolone at a starting dose of 1 mg/kg body weight per day; this therapy was tapered during the next 21-28 days. In 20 patients with profound hearing loss (>70 dB), 3 boluses of prednisolone-21-hydrogen-succinate (500 mg per day) were administered. After receiving the boluses, these patients continued with the oral 6-methylprednisolone scheme.
  
  
  RESULTS
  Mild adverse effects were observed in 16 patients (7.01%). Only 2 patients (0.9%) with sudden sensorineural hearing loss showed severe complications: peptic ulcer and avascular necrosis of the femoral heads.
  
  
  CONCLUSIONS
  The low percentage of severe adverse effects observed in the present study validates the use of corticosteroids for the treatment of inner ear disorders although we should not underestimate these rare complications.
authors.affiliation: Service of Otorhinolaryngology, Hospital Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: José Ramón
authors.initials: JR
authors.lastname: García-Berrocal
authors.forename: Rafael
authors.initials: R
authors.lastname: Ramírez-Camacho
authors.forename: David
authors.initials: D
authors.lastname: Lobo
authors.forename: Almudena
authors.initials: A
authors.lastname: Trinidad
authors.forename: José María
authors.initials: JM
authors.lastname: Verdaguer
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D003639:Hearing Loss, Sudden / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007759:Labyrinth Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology
chemical_list: D005938:Glucocorticoids